InsiderTradesSIGMA

PicksTOP Companies Executives Performance Blog Topics

InsidersTradesSigma

InsiderTradesSIGMA

Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta.

FRUSDEGBCHCAITESNLBENOSEFIDKAUATIEBRINJP+ 8 markets

Recommendations
Companies
Insiders
Performance
Backtest
Compare

Methodology
How it works
Glossary
API docs
Status
Blog

Sign in
Create account
Portfolio
API keys
Alerts
Upgrade

Privacy
Terms
Cookies
Contact
About

Built in Paris. Public sources across 28 markets: AMF France, SEC EDGAR Form 4 US, BaFin Germany, SIX SER Switzerland, RNS United Kingdom, SEDI Canada, Consob Italy, CNMV Spain, AFM Netherlands, FSMA Belgium, Oslo Bors Norway, Nasdaq Helsinki, Nasdaq Copenhagen, ASX Australia, FMA Austria, CVM Brazil, HKEX Hong Kong, BSE-Sofia Bulgaria, Tadawul Saudi Arabia, DART South Korea, EDINET Japan, SSE and SZSE China, SEBI India, KNF Poland, PSE Philippines, NZX New Zealand, JSE South Africa. Prices + fundamentals via Yahoo Finance, STOXX 600 sector ETFs (iShares Xetra). Stack: Next.js 16, Prisma, Vercel. Live out-of-sample tracker since 2026-05-16. Methodology audits: /methodologie and /docs/method-review/.

Sources: official public filings under MAR Art.19 (EU and EEA), SEC Section 16 / Form 4 (US), Art.56 SESTA (CH, SIX SER), NI 55-104 / SEDI (CA), Corporations Act s205G (AU) and equivalent regimes. Signals on this site are for educational use only and do not constitute investment advice within the meaning of MiFID II / SEC Reg-IA. Past performance does not guarantee future results. Swiss SIX SER filings are anonymised by law (role only, no name).

Theme: dark (range regime detected on CAC40 90d · as of 2026-05-25)

© 2026 Insiders TradesΣ·Private beta·Hosted on Vercel

All systems operational

InsidersTradesSigma

HLB · Dirigeant — insider filings · 28 reports

← Executives ★ Sign in to follow

H

HLB

Dirigeant

Other

KRKR·DART (FSS)

HLB바이오스텝 HLB이노베이션 HLB제넥스 HLB테라퓨틱스 HLB파나진 HLB테라퓨틱스 HLB제넥스 HLB펩 HLB펩 HLB파나진

Cumul. flow

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Explore the complete record of transactions filed by HLB, Dirigeant. Insider active across 10 companies, notably HLB바이오스텝. In total, 28 disclosures have been logged. The latest transaction was filed on 15 May 2026 — Purchase. Regulator: DART (FSS). The full history is openly available.

Declarations28 total

Executives●PurchaseHHLB이노베이션5DART

H

€5m385,507 shares

KRX

DART:20260515000502·15 May 2026

Ideal exit: 9 Feb 2027 (T+270)

Executives●SaleHHLB바이오스텝2DART

H

€39m14,087,156 shares

KRX

DART:20260511000277·11 May 2026

Executives●SaleHHLB이노베이션5DART

H

ShareKRX

DART:20260511000281·11 May 2026

Executives●SaleHHLB이노베이션5DART

H

€559m45,194,374 shares

KRX

DART:20260511000289·11 May 2026

Executives●SaleHHLB바이오스텝2DART

H

ShareKRX

DART:20260511000270·11 May 2026

Executives●PurchaseHHLB제넥스2DART

H

€29,41515,556 shares

KRX

DART:20260421000005·21 Apr 2026

Ideal exit: 16 Jan 2027 (T+270)

Executives●OtherHHLB테라퓨틱스3DART

H

0

KRX

DART:20260421000440·21 Apr 2026

Executives●PurchaseHHLB제넥스2DART

H

€124,44068,401 shares

KRX

DART:20260416000156·16 Apr 2026

Ideal exit: 11 Jan 2027 (T+270)

Executives●SaleHHLB펩2DART

H

721,900 shares

KRX

DART:20260416000002·16 Apr 2026

Executives●PurchaseHHLB펩10DART

H

€91,61222,045 shares@ €4.15570.0001% mcap100.0% of flow

ShareKRX

DART:20260415000249·8 Apr 2026

Ideal exit: 3 Jan 2027 (T+270)

Executives●PurchaseHHLB펩2DART

H

144,200 shares

KRX

DART:20260403002757·3 Apr 2026

Ideal exit: 29 Dec 2026 (T+270)

Executives●PurchaseHHLB이노베이션5DART

H

€3m210,000 shares

KRX

DART:20260403001050·3 Apr 2026

Ideal exit: 29 Dec 2026 (T+270)

Executives●PurchaseHHLB제넥스2DART

H

€90,56459,619 shares

KRX

DART:20260401001403·1 Apr 2026

Ideal exit: 27 Dec 2026 (T+270)

Executives●PurchaseHHLB테라퓨틱스3DART

H

ShareKRX

DART:20260319000770·19 Mar 2026

Ideal exit: 14 Dec 2026 (T+270)

Executives●PurchaseHHLB제넥스10DART

H

€473,393307,748 shares@ €1.53820.0006% mcap100.0% of flow

ShareKRX

DART:20260319000780·12 Mar 2026

Ideal exit: 7 Dec 2026 (T+270)

Executives●PurchaseHHLB제넥스2DART

H

€496,203312,204 shares

KRX

DART:20260319000790·19 Mar 2026

Ideal exit: 14 Dec 2026 (T+270)

Executives●PurchaseHHLB테라퓨틱스3DART

H

€1m714,664 shares

KRX

DART:20260317000251·17 Mar 2026

Ideal exit: 12 Dec 2026 (T+270)

Executives●PurchaseHHLB이노베이션5DART

H

€108,0889,000 shares

KRX

DART:20260317000257·17 Mar 2026

Ideal exit: 12 Dec 2026 (T+270)

Executives●PurchaseHHLB파나진2DART

H

€26,23520,000 shares

KRX

DART:20260317000246·17 Mar 2026

Ideal exit: 12 Dec 2026 (T+270)

Executives●OtherHHLB펩0DART

DART:20260312000848·12 Mar 2026details not loaded

Executives●OtherHHLB바이오스텝0DART

DART:20260311004013·11 Mar 2026details not loaded

Executives●SaleHHLB파나진2DART

H

€4m3,195,475 shares

KRX

DART:20260310002201·10 Mar 2026

Executives●PurchaseHHLB파나진10DART

H

€5m3,266,475 shares@ €1.43650.0061% mcap100.0% of flow

ShareKRX

DART:20260310002197·5 Mar 2026

Ideal exit: 30 Nov 2026 (T+270)

Executives●PurchaseHHLB이노베이션5DART

H

€338,47438,000 shares

KRX

DART:20260310002204·10 Mar 2026

Ideal exit: 5 Dec 2026 (T+270)

Executives●PurchaseHHLB테라퓨틱스3DART

H

€54,33133,000 shares

KRX

DART:20260310002207·10 Mar 2026

Ideal exit: 5 Dec 2026 (T+270)

25 of 28 declarations

About HLB

HLB is a company associated with HLB이노베이션. While details about the executives' roles are not provided, HLB is active in the technology innovation sector, offering various solutions. The company is committed to innovating and meeting market demands.